With technology to perfect product pitches in digital marketplaces Pattern raises $52 million

Pattern, a Lehi, Utah-based reseller that offers large and small brands a way to optimize their sales on marketplaces like Amazon, eBay, Walmart and Google Shopping, has raised $52 million in growth funding, the company said.

The money, from Ainge Advisory and KSV Global, will be used to expand the company’s business worldwide.

Founded in 2013, the e-commerce reseller uses analytics to lock down market specific keywords in advertising and has managed to reach a run-rate that should see it hit $500 million in annual revenue by the end of 2020, according to Pattern co-founder and chief investment officer, Melanie Alder.

Brands like Nestle, Pandora, Panasonic, Zebra and Skechers sell their goods to Pattern in an effort to juice sales on digital marketplaces.

“Pattern represents our brands in the US, across Europe, and in select markets in Asia, selling for us on global marketplaces such as Amazon, Walmart, Tmall, and JD as well as building and managing three of our direct-to-consumer sites,” said Kyle Bliffert, CEO and president of Atrium Innovations, a Nestle Health Science company, in a statement. “The global e-commerce growth we have experienced by leveraging Pattern’s expertise is extraordinary.”

Pattern places bets on where a product is likely to receive the most attention using specific keywords, according to the company’s chief executive, Dave Wright. The company buys products from its brand partners and then sells them widely across marketplaces in the US, Europe and Asia. These markets represent $2.7 trillion in total sales and Wright expects it to reach $7 trillion by 2024.

As Wright noted, a majority of searchers for sales begin on Amazon . The company just opened its eighteenth location in Germany. Pattern has grown sales for brands from $3 million to $26 million and the company makes money off of the margin on the sales of products. With the new funding, the company intends to expand into other geographies like Japan and India.

Wright says his company addresses one of the fundamental problems with advertising technology — the proliferation of tools hasn’t meant better optimization for most brands, because they’re teams aren’t equipped to specialize.

While there may be hundreds of different advertising and marketing folks working at a company, each company may have hundreds of brands that it sells and the dedicated teams to specific brands may only have one or two  people on staff.

“Data makes all the difference,” said co-founder and CEO Dave Wright. “I’ve spent the bulk of my career in data science and data management, and our ability to detect and act on ‘patterns’ on ecommerce platforms has allowed the brands we represent to be incredibly successful.”

Focusing on human and climate health, S2G Ventures launches ocean fund with $100 million in commitments

S2G Ventures, the Chicago-based investment firm focusing on startups developing technology and services for human and planetary health, is launching a new investment vehicle focused on seafood and oceanic cultivation.

The firm was an investor in Beyond Meat, the $9 billion-valued publicly traded meat replacement startups that’s been one of the biggest recent success stories in the market for food science startups. It also holds stakes in companies like the healthy food chain, Sweetgreen, the microbial meat replacement technology developer Future Meat Technologies, robotic harvesting tech developer, Augean Robotics, food preservation technology developer Apeel, and other food and agriculture-focused tech companies.

Now the firm is turning its attention to the oceans. It has already received commitments for $100 million in new capital to finance the endeavor and added Kate Danaher, the former chief lending officer at RSF Social Finance, and Larsen Mettler, the former owner and chief financial officer of Silver Bay Seafoods as managing directors to oversee the oceans and seafood strategy.

The new investment vehicle will invest in early, venture, and growth stage companies globally that are developing alternative proteins and seafood, aquaculture, supply chain innovaiton, transparency, algae and seaweed cultivation and commercialization and ecosystem services, according to a statement.

GettyImages 1140243144

IZMIR, TURKEY – APRIL 25 : An aerial view of fish farm, raising a new breed ‘Egeli’ fish, in Izmir’s Karaburun district, Turkey on April 25, 2019. ‘Egeli’ fish, cross breeding of sea bream and dentex, are expected to be put on sale in a year. (Photo by Mahmut Serdar Alakus/Anadolu Agency/Getty Images)

Seafood is a primary source of protein for 3 billion people around the world, and as consumers look to lower their meat consumption, many more are turning to fish and seafood as their alternative. According the United Nations panel on climate change, oceans have already absorbed over 90 percent of the excess heat trapped in the climate system.

The warming is causing significant changes in currents and sea levels, which affect the health of marine species, nearshore and deep ocean ecosystems, as well as weather systems across the globe, the firm said.

Any solution to climate change will need to address the acidification and overheating that the oceans have endured as the first victim of the world’s evolving climate catastrophe.

Nurx has $22.5 million in new money, a path to profitability, and new treatments for migraines on the way

As the COVID-19 epidemic spread across the US earlier this year, Nurx, like most other digital providers of healthcare and prescription services saw a huge spike in demand.

Now, with $22.5 million in new financing and a surging annual run rate that could see the company hit $150 million in revenue, the company is emerging as the largest digital practice for women’s health.

“We saw this tremendous surge in need for our contraception and sensitive health services,” says Nurx chief executive Varsha Rao .

The growth hasn’t come without controversy. Only last year, a New York Times article pointed to corner cutting at the startup which boasts Chelsea Clinton as an investor and advisor.

Undeterred Rao said that the company has now seen tremendous acceleration in all areas of its business. It’s now providing care to over 300,000 patients on a monthly basis, boasts that $150 million run rate and new investors like Comcast Ventures, Trustbridge and Wittington Ventures — the investment arm of one of the largest pharmacy chains in Canada, Shoppers Drug Mart.

The new $22.5 million is an extension on the company’s previous $32 million round and will take the company to profitability by 2021, according to Rao.

And while birth control and contraception are still the largest areas of the company’s business, Nurx is growing its range of services, seeing adoption of its testing for sexually transmitted infections including HPV and herpes and a new treatment area for migraines.

That focus on sexual health and what the company calls sensitive health is different from trying to be a primary care provider says Rao. “Our real focus right now is on our core demographic who are women between the ages of twenty and forty and really focusing on their needs,” she says. “That’s why migraines make a lot of sense. It’s not exclusively hormone related, but it often is… One-in-four women experience migraines and they’re largely from hormonal changes… This is a condition we’re well positioned to address.”

Another way that Nurx differentiates itself from competitors like Hims and Ro, which provide women’s health and contraceptive prescriptions as well, is through its ability to take insurance. “It’s actually pretty challenging to build the system to actually offer insurance,” says Rao. “And yet, we don’t think you can be a true healthcare company if you don’t accept insurance.”

 

With former Misfit founder Sonny Vu at the helm, Arevo raises $25 million for its 3D printing tech

Sonny Vu, the former founder and chief executive of the wearable technology company, Misfit, has had a busy summer since he was named the new chief executive of 3D printing technology company, Arevo.

Vu’s new startup brought on a new executive management team, launched a crowdfunding campaign for its 3D printed Superstrata bicycle and is now announcing the close of a $25 million financing round to support the growth of its business.

It’d be a lot for anyone to take on even if it didn’t happen in the middle of global pandemic. But Vu, a serial entrepreneur whose last business went head-to-head with Apple before it was acquired by Fossil for $260 million, doesn’t shy away from challenges.

Vu was first introduced to Arevo in 2019 and was initially going to come on as an advisor to the company. Since the acquisition of Misfit he had been investing from Alabaster, his personal investment vehicle. First introduced by Vinod Khosla, an investor in the business, Vu quickly moved from being an advisor to an executive at the helm of the business and an investor providing bridge financing until the company could close its latest round.

Vu had initially intended to start his own business, but was drawn to Arevo’s potential. “3D printing is about making things slowly and in small quantities. With Arevo’s technology you can make big things quite fast,” Vu said in an interview.

Several companies are attempting to take 3D printing into heavy industry and large scale manufacturing. Relativity raised $140 million in its most recent financing to make rockets using 3D printers, Velo3D is a supplier of 3D printers to SpaceX, and now Arevo has $34 million for its efforts to scale 3d printers. Of course all of these investments pale in comparison to the whopping $438 million that Desktop Metal has raised for its 3D printing tech.

“Arevo is a compelling opportunity for us as it combines our three main investment foci: consumer internet, enterprise, and smart tech. We see fantastic potential in this market, and have backed Sonny before at Misfit,” said Hans Tung, in a statement. “Arevo is led by an experienced team with solid technological foundation and 3D printing manufacturing know-how at scale – to offer breakthrough products at competitive prices.”

Arevo already has a successful proof of concept with its Superstrata bicycle and manufacturing facilities in Vietnam that are intended to prove that the company’s technology will work as expected.

“We’re making this bike to make a point that we can make complex shapes at a pretty large scale,” Vu said. Unlike other companies that sell their printers to manufacturers, Arevo intends to sell parts. That’s because the printers are a pretty hefty ticket for anyone to buy. At $1 million to $1.4 million, it’s a big ask for a company to acquire if it wants to start using 3D printing.

On top of that cost, Vu said candidly that the company’s Achilles heel was the post-manufacturing treatment process required to finish the pieces. And while Arevo already counts automotive and aerospace companies as customers (including Airbus, which previously invested in the business), Vu wants to bring this to consumers. “We’ve had tennis racquet companies, golf clubs, surfboards,” approach Arevo about using the company’s technology, Vu says.

“We can do about two frames per day per machine,” Vu says of the latest production rates. “And coming up with our next gen system we can do about six frames per day.”

The ascension of Vu to the chief executive position and the new capital infusion marks the latest chapter for Arevo which is on its third chief executive since it was founded. Two years ago, Jim Miller, a former Amazon and Google executive, was brought on board to take the reins at the company. Miller’s appointment coincided with a $12.5 million investment round led by Asahi Glass, with Sumitomo Corp., Leslie Ventures and Khosla Ventures participating. Miller was involved with collaborating with Studio West on the design of its Superstrata bike.

Now, Defy Partners and GGV Capital are joining to lead the company’s Series B round with participation from Khosla Ventures, Alabaster and others. Brian Shin, a scout with Defy Ventures is joining the board which now counts Bruce Armstrong, from Khosla Ventures, and Hemant Bheda, Arevo’s co-founder as directors (along with Vu).

“Arevo’s new platform enables fabrication of high strength, low weight carbon fiber parts, currently not possible with today’s standard techniques,” said Trae Vassallo, founding partner at Defy. “We are thrilled to be working with the team to help scale up this incredibly impactful technology.”

With former Misfit founder Sonny Vu at the helm, Arevo raises $25 million for its 3D printing tech

Sonny Vu, the former founder and chief executive of the wearable technology company, Misfit, has had a busy summer since he was named the new chief executive of 3D printing technology company, Arevo.

Vu’s new startup brought on a new executive management team, launched a crowdfunding campaign for its 3D printed Superstrata bicycle and is now announcing the close of a $25 million financing round to support the growth of its business.

It’d be a lot for anyone to take on even if it didn’t happen in the middle of global pandemic. But Vu, a serial entrepreneur whose last business went head-to-head with Apple before it was acquired by Fossil for $260 million, doesn’t shy away from challenges.

Vu was first introduced to Arevo in 2019 and was initially going to come on as an advisor to the company. Since the acquisition of Misfit he had been investing from Alabaster, his personal investment vehicle. First introduced by Vinod Khosla, an investor in the business, Vu quickly moved from being an advisor to an executive at the helm of the business and an investor providing bridge financing until the company could close its latest round.

Vu had initially intended to start his own business, but was drawn to Arevo’s potential. “3D printing is about making things slowly and in small quantities. With Arevo’s technology you can make big things quite fast,” Vu said in an interview.

Several companies are attempting to take 3D printing into heavy industry and large scale manufacturing. Relativity raised $140 million in its most recent financing to make rockets using 3D printers, Velo3D is a supplier of 3D printers to SpaceX, and now Arevo has $34 million for its efforts to scale 3d printers. Of course all of these investments pale in comparison to the whopping $438 million that Desktop Metal has raised for its 3D printing tech.

“Arevo is a compelling opportunity for us as it combines our three main investment foci: consumer internet, enterprise, and smart tech. We see fantastic potential in this market, and have backed Sonny before at Misfit,” said Hans Tung, in a statement. “Arevo is led by an experienced team with solid technological foundation and 3D printing manufacturing know-how at scale – to offer breakthrough products at competitive prices.”

Arevo already has a successful proof of concept with its Superstrata bicycle and manufacturing facilities in Vietnam that are intended to prove that the company’s technology will work as expected.

“We’re making this bike to make a point that we can make complex shapes at a pretty large scale,” Vu said. Unlike other companies that sell their printers to manufacturers, Arevo intends to sell parts. That’s because the printers are a pretty hefty ticket for anyone to buy. At $1 million to $1.4 million, it’s a big ask for a company to acquire if it wants to start using 3D printing.

On top of that cost, Vu said candidly that the company’s Achilles heel was the post-manufacturing treatment process required to finish the pieces. And while Arevo already counts automotive and aerospace companies as customers (including Airbus, which previously invested in the business), Vu wants to bring this to consumers. “We’ve had tennis racquet companies, golf clubs, surfboards,” approach Arevo about using the company’s technology, Vu says.

“We can do about two frames per day per machine,” Vu says of the latest production rates. “And coming up with our next gen system we can do about six frames per day.”

The ascension of Vu to the chief executive position and the new capital infusion marks the latest chapter for Arevo which is on its third chief executive since it was founded. Two years ago, Jim Miller, a former Amazon and Google executive, was brought on board to take the reins at the company. Miller’s appointment coincided with a $12.5 million investment round led by Asahi Glass, with Sumitomo Corp., Leslie Ventures and Khosla Ventures participating. Miller was involved with collaborating with Studio West on the design of its Superstrata bike.

Now, Defy Partners and GGV Capital are joining to lead the company’s Series B round with participation from Khosla Ventures, Alabaster and others. Brian Shin, a scout with Defy Ventures is joining the board which now counts Bruce Armstrong, from Khosla Ventures, and Hemant Bheda, Arevo’s co-founder as directors (along with Vu).

“Arevo’s new platform enables fabrication of high strength, low weight carbon fiber parts, currently not possible with today’s standard techniques,” said Trae Vassallo, founding partner at Defy. “We are thrilled to be working with the team to help scale up this incredibly impactful technology.”

Atomwise’s machine learning-based drug discovery service raises $123 million

With a slew of partnerships with large pharmaceutical companies under its belt and the successful spin out of at least one new company, Atomwise has already proved the value of its machine learning platform for discovering and commercializing potential small molecule therapies for a host of conditions.

Now the company has raised $123 million in new funding to accelerate its business.

“Scaling the technology and scaling the team and scaling what we’ve been doing with it,” says chief executive officer Abe Heifets when asked about what comes next for the eight year old business.

Atomwise has already signed contracts worth $5.5 billion with corporate partners that include Eli Lilly & Co., Bayer, Hansoh Pharmaceuticals, and Bridge Biotherapeutics. Smaller, earlier stage companies like StemoniX and SEngine Precision Medicine are also using Atomwise’s tech.

Now the company will look to capture more of the value of drug discovery for itself, looking to develop and commercialize its discoveries by taking over more of the development process and working with manufacturers at a later stage, according to Heifets.

Atomwise tipped its new strategy last year when it announced a partnership with Velocity Drug Development and a $14.5 million investment to create x-37, a spinoff that’s developing small molecule therapies for endodermal cancers, which include cancers of the liver, pancreas, colon, stomach, and bladder.

“We have something like 750 projects running today around the world,” says Heifets. “These comprise more than 600 unique targets and that’s with a vast range of partnerships.”

The power of Atomwise’s drug discovery platform is its ability to harness machine learning to structure new proteins that have never existed — and ensure that they’re able to reach precise target receptors to accomplish a desired task.

Here, the x-37 spinoff is especially illustrative. One line of research the company is conducting into molecules that can target the PIM3 protein receptor. If a drug can block PIM3, it can kill cancerous endodermal cells, according to Heifets. However, if the molecules bind to another, similar target, PIM1, the therapy can cause heart attacks and kill patients.

“This is a challenge and empirically was considered undruggable,” says Heifets. Atomwise’s company screened 11 billion potential molecules against the targets to come up with 500 potential therapies. They’re now working on refining the therapy to bring something to market.

And x-37 is only one of the companies that Atomwise has created to commercialize various new molecules. There’s also Atropos Therapeutics, Theia Biosciences and vAIrus.

Atomwise is far from the only company to think that the application of machine learning technologies to drug discovery is a winning combination. Menten.ai is a company that’s taken the new technology developments one step further and added quantum computing to the mix to come up with new drugs.

“The market opportunity we’re going after is four times the value of the entire pharma industry today,” said Heifets. “Here’s what that’s about. There’s 20,000 human genes and only 4% have ever been drugs. Another 16% have been evidenced. But the opportunity of drugging the undruggable is way bigger than the entire pharma industry.”

Unlocking that opportunity is going to take lots of capital. That’s why B Capital and Sanabil Investments combined to lead Atomwise’s Series B round. It’s also why companies like DCVC, BV, Tencent, Y Combinator, Dolby Ventures, AME Cloud Ventures and two, undisclosed, insurance companies have invested in the company’s latest round.

 with a goal to commercialize high potential candidates through the drug development process. The company plans to continue to expand its work with corporate partners, which currently include major players in the biopharma space including Eli Lilly and Company, Bayer, Hansoh Pharmaceuticals, and Bridge Biotherapeutics, as well as emerging biotechnology companies like StemoniX and SEngine Precision Medicine. Atomwise has signed approximately $5.5 billion in deal value with corporate partners to date.

To date, Atomwise has worked with 750 academic research collaborations addressing over 600 disease targets, to model and screen over 16 billion new molecules for virtual screening. These molecules have generated 17 pending patent applications and several peer-reviewed publications. There are 285 active drug discovery partnerships with researchers at top universities around the world, and recently announced 15 research collaborations with global universities to explore broad-spectrum therapies for COVID-19, targeting 15 unique and novel mechanisms of action.

“New technologies are enabling better and faster R&D for the life science industry,” said Raj Ganguly, co-Founder and Managing Partner at B Capital Group . “The advancements Atomwise has made with its computational drug discovery platform have effectively cut months or even years off of the R&D lifecycle. More importantly, however, they are solving biology problems previously believed to be unsolvable by researchers and delivering that capability to everyone from academics to big pharma. We’re excited to continue to partner with the Atomwise team on its mission to develop new, more effective therapies.”

For lead investor, B Capital, the Atomwise investment is part of a thesis around lowering the cost of care and improving outcomes.

“Companies like Atomwise that are improving the cost curve are in the same vein of bringing therapies to market faster and cheaper. Which means you can improve access and improve costs and address things like rare diseases,” said Adam Seabrook, a principal at B Capital focused on healthcare.

Atomwise’s machine learning-based drug discovery service raises $123 million

With a slew of partnerships with large pharmaceutical companies under its belt and the successful spin out of at least one new company, Atomwise has already proved the value of its machine learning platform for discovering and commercializing potential small molecule therapies for a host of conditions.

Now the company has raised $123 million in new funding to accelerate its business.

“Scaling the technology and scaling the team and scaling what we’ve been doing with it,” says chief executive officer Abe Heifets when asked about what comes next for the eight year old business.

Atomwise has already signed contracts worth $5.5 billion with corporate partners that include Eli Lilly & Co., Bayer, Hansoh Pharmaceuticals, and Bridge Biotherapeutics. Smaller, earlier stage companies like StemoniX and SEngine Precision Medicine are also using Atomwise’s tech.

Now the company will look to capture more of the value of drug discovery for itself, looking to develop and commercialize its discoveries by taking over more of the development process and working with manufacturers at a later stage, according to Heifets.

Atomwise tipped its new strategy last year when it announced a partnership with Velocity Drug Development and a $14.5 million investment to create x-37, a spinoff that’s developing small molecule therapies for endodermal cancers, which include cancers of the liver, pancreas, colon, stomach, and bladder.

“We have something like 750 projects running today around the world,” says Heifets. “These comprise more than 600 unique targets and that’s with a vast range of partnerships.”

The power of Atomwise’s drug discovery platform is its ability to harness machine learning to structure new proteins that have never existed — and ensure that they’re able to reach precise target receptors to accomplish a desired task.

Here, the x-37 spinoff is especially illustrative. One line of research the company is conducting into molecules that can target the PIM3 protein receptor. If a drug can block PIM3, it can kill cancerous endodermal cells, according to Heifets. However, if the molecules bind to another, similar target, PIM1, the therapy can cause heart attacks and kill patients.

“This is a challenge and empirically was considered undruggable,” says Heifets. Atomwise’s company screened 11 billion potential molecules against the targets to come up with 500 potential therapies. They’re now working on refining the therapy to bring something to market.

And x-37 is only one of the companies that Atomwise has created to commercialize various new molecules. There’s also Atropos Therapeutics, Theia Biosciences and vAIrus.

Atomwise is far from the only company to think that the application of machine learning technologies to drug discovery is a winning combination. Menten.ai is a company that’s taken the new technology developments one step further and added quantum computing to the mix to come up with new drugs.

“The market opportunity we’re going after is four times the value of the entire pharma industry today,” said Heifets. “Here’s what that’s about. There’s 20,000 human genes and only 4% have ever been drugs. Another 16% have been evidenced. But the opportunity of drugging the undruggable is way bigger than the entire pharma industry.”

Unlocking that opportunity is going to take lots of capital. That’s why B Capital and Sanabil Investments combined to lead Atomwise’s Series B round. It’s also why companies like DCVC, BV, Tencent, Y Combinator, Dolby Ventures, AME Cloud Ventures and two, undisclosed, insurance companies have invested in the company’s latest round.

 with a goal to commercialize high potential candidates through the drug development process. The company plans to continue to expand its work with corporate partners, which currently include major players in the biopharma space including Eli Lilly and Company, Bayer, Hansoh Pharmaceuticals, and Bridge Biotherapeutics, as well as emerging biotechnology companies like StemoniX and SEngine Precision Medicine. Atomwise has signed approximately $5.5 billion in deal value with corporate partners to date.

To date, Atomwise has worked with 750 academic research collaborations addressing over 600 disease targets, to model and screen over 16 billion new molecules for virtual screening. These molecules have generated 17 pending patent applications and several peer-reviewed publications. There are 285 active drug discovery partnerships with researchers at top universities around the world, and recently announced 15 research collaborations with global universities to explore broad-spectrum therapies for COVID-19, targeting 15 unique and novel mechanisms of action.

“New technologies are enabling better and faster R&D for the life science industry,” said Raj Ganguly, co-Founder and Managing Partner at B Capital Group . “The advancements Atomwise has made with its computational drug discovery platform have effectively cut months or even years off of the R&D lifecycle. More importantly, however, they are solving biology problems previously believed to be unsolvable by researchers and delivering that capability to everyone from academics to big pharma. We’re excited to continue to partner with the Atomwise team on its mission to develop new, more effective therapies.”

For lead investor, B Capital, the Atomwise investment is part of a thesis around lowering the cost of care and improving outcomes.

“Companies like Atomwise that are improving the cost curve are in the same vein of bringing therapies to market faster and cheaper. Which means you can improve access and improve costs and address things like rare diseases,” said Adam Seabrook, a principal at B Capital focused on healthcare.

Abandoned mall department stores may become Amazon’s next fulfillment center

One of the largest owners of shopping mall real estate in the United Stages, Simon Property Group, has been talking to Amazon about transforming its anchor department stores into Amazon distribution hubs, according to the Wall Street Journal.

In the case of Simon Property, the anchor tenants like J.C. Penney and Sears that used to be stable sources of revenue are now weights around the neck of the retail real estate manager, and transforming their ghostly halls of pale mannequins into warehouses for Amazon orders simply makes sense.

The transformation from showroom to storehouse for everything from books and sweaters to kitchenware and electronics won’t be too much of a stretch for the vacant storefronts of businesses that hvae both filed for Chapter 11 bankruptcy protection.

Simon’s holdings include some 63 JC Penney and 11 Sears stores, according to the Journal’s reporting citing a May public filing from the real estate developer.

This wouldn’t be the first time that Amazon had turned to mall real estate for fulfillment centers. in 2019, the online retailer acquired a massive physical footprint in Akron, Ohio that it turned into a distribution center.

Gone are the days when gum smacking tweens and teens and their beleaguered parents would head to the local mall for a stroll around the retail block. Now shoppers prefer to peruse online and kids find Fortnite to be the Hot Topic to hang in. 

The deal, if it goes through, would be another nail in the coffin for a staple of late twentieth century culture that now mostly exists in the memory of baby boomers and Gen X consumers (thanks millennials and Gen Z).

Malls these days are lifestyle affairs that promise boutique branded shops than the sprawling department stores that had something for everyone. The big-box spaces that the Journal reported Amazon is negotiating for are the 100,000 square foot, multi-story behemoths, that are likely not long for the long tail world of niche commerce anyway.

These days, consumers are looking for brands that appeal to a persona or the bottom line of a pocketbook, and not the mass casual one-stop-shop of late twentieth century department store off-the-rack identities.

The Journal reported that, if the deals went through, Simon would like rent the space at a considerable discount to what it would charge another retailer. The paper estimated that rents could be as low as $4 per square foot to $19 per square foot, while warehouse rents average about $10.

At this point, shopping malls are looking for anything to bring in money. They’ve already tried schools, medical offices and senior living facilities, but the COVID-19 epidemic has thrown all of those plans into the abyss.

And, as the Journal notes, malls are already located in places that make them attractive distribution hubs. Amazon has bought some sites already and FedEx and DHL have done the same, according to the paper.

At this point, Amazon ownership may be a better fate for the real estate than totally abandoning it to empty space and the lingering soundtrack of 80s rock.

 

Abandoned mall department stores may become Amazon’s next fulfillment center

One of the largest owners of shopping mall real estate in the United Stages, Simon Property Group, has been talking to Amazon about transforming its anchor department stores into Amazon distribution hubs, according to the Wall Street Journal.

In the case of Simon Property, the anchor tenants like J.C. Penney and Sears that used to be stable sources of revenue are now weights around the neck of the retail real estate manager, and transforming their ghostly halls of pale mannequins into warehouses for Amazon orders simply makes sense.

The transformation from showroom to storehouse for everything from books and sweaters to kitchenware and electronics won’t be too much of a stretch for the vacant storefronts of businesses that hvae both filed for Chapter 11 bankruptcy protection.

Simon’s holdings include some 63 JC Penney and 11 Sears stores, according to the Journal’s reporting citing a May public filing from the real estate developer.

This wouldn’t be the first time that Amazon had turned to mall real estate for fulfillment centers. in 2019, the online retailer acquired a massive physical footprint in Akron, Ohio that it turned into a distribution center.

Gone are the days when gum smacking tweens and teens and their beleaguered parents would head to the local mall for a stroll around the retail block. Now shoppers prefer to peruse online and kids find Fortnite to be the Hot Topic to hang in. 

The deal, if it goes through, would be another nail in the coffin for a staple of late twentieth century culture that now mostly exists in the memory of baby boomers and Gen X consumers (thanks millennials and Gen Z).

Malls these days are lifestyle affairs that promise boutique branded shops than the sprawling department stores that had something for everyone. The big-box spaces that the Journal reported Amazon is negotiating for are the 100,000 square foot, multi-story behemoths, that are likely not long for the long tail world of niche commerce anyway.

These days, consumers are looking for brands that appeal to a persona or the bottom line of a pocketbook, and not the mass casual one-stop-shop of late twentieth century department store off-the-rack identities.

The Journal reported that, if the deals went through, Simon would like rent the space at a considerable discount to what it would charge another retailer. The paper estimated that rents could be as low as $4 per square foot to $19 per square foot, while warehouse rents average about $10.

At this point, shopping malls are looking for anything to bring in money. They’ve already tried schools, medical offices and senior living facilities, but the COVID-19 epidemic has thrown all of those plans into the abyss.

And, as the Journal notes, malls are already located in places that make them attractive distribution hubs. Amazon has bought some sites already and FedEx and DHL have done the same, according to the paper.

At this point, Amazon ownership may be a better fate for the real estate than totally abandoning it to empty space and the lingering soundtrack of 80s rock.

 

VenoStent has a new technology to improve outcomes for dialysis patients

Timothy Bouré and his co-founder Geoffrey Lucks were both near broke when they moved to Dallas to join the first accelerator they entered after forming VenoStent, a company that aims to improve outcomes for dialysis patients.

Failed dialysis surgeries occur in roughly 55% to 65% of patients with end-stage renal disease, according to the company. Caring for these patients can cost the Medicare and Medicaid Services system roughly $2 billion per year — and Bouré and Lucks believed that they’d come up with a solution.

So after years developing the technology at the core of VenoStent’s business at Vanderbilt University, the two men relocated from Nashville to South Texas to make their business work.

Bouré had first started working on the technology at the heart of VenoStent’s offering as part of his dissertation in 2012. Lucks, a graduate student at the business school was introduced to the material scientist and became convinced that VenoStent was on the verge of having a huge impact for the medical community. Five years later, the two were in Dallas where they met the chief of vascular surgery at Houston Medicine and were off to the races.

A small seed round in 2018 kept the company going and a successful animal trial near the end of the year gave it the momentum it needed to push forward. Now, as it graduates from the latest Y Combinator cohort, the company is finally ready for prime time.

In the interim, a series of grants and its award of a Kidney XPrize kept the company in business.

The success was hard won, as Bouré spent nearly three sleepless nights in the J-Labs, Johnson and Johnson’s  medical technology and innovation accelerator in Houston, synthesizing polymers and printing the sleeve stents that the company makes to keep replace the risky and failure-prone surgeries for end stage kidney disease patients.

The key discovery that Bouré made was around a new type of polymer that can be used to support cell growth as it heals from the dialysis surgery.

In 2012, Bouré stumbled upon the polymer that would be the foundation for the work. Then, in 2014, he did the National Science Foundation Core program and started thinking about the wrap for blood vessels. Through a series of discussions with vascular surgeons he realized that the problem was especially acute for end stage renal disease patients.

Already the company has raised $2.4 million in grant funding and small equity infusions. and the KidneyX Prize from the Department of Health and Human Services and the American Society of Nephrology. VenoStent was one of six winners.

“It’s part of this whole ongoing effort by the executive office to improve dialysis,” said Bouré. “[They are] some of the most expensive patients to treat in the world… Basically the government is highly incentivized to find technologies that improve patient’s lives.”

Now the company is heading into its next round of animal testing and will seek to conduct its first human trials outside of the United States in 2021.

And while the company is focused on renal failure first, the materials that Bouré has developed have applications for other conditions as well. “This can be a material for the large intestine,” says Bouré. “It has tunability in terms of all its properties. And we can modify it for a particular application.”